A pair of late-stage trials found that Eli Lilly’s experimental once-weekly insulin can lower blood sugar as effectively as ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

New data show Lilly’s longer-lasting insulin matched daily shots in controlling blood sugar, adding to positive findings the company disclosed in May.

Eli Lilly said a once-weekly dose of insulin efsitora proved to reduce hemoglobin A1C in a Qwint-2 Phase 3 trial when compared with a daily dose of insulin in people with type 2 diabetes using insulin ...

A pair of late-stage trials found that Eli Lilly & Co.’s experimental ... with Novo Nordisk to develop longer-acting insulins. Lilly’s once-weekly insulin, efsitora alfa, reduced the A1C ...

Thursday, Eli Lilly and Co (NYSE:LLY) released topline results from the QWINT-1 and QWINT-3 phase 3 trials evaluating once weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes.

New research offers an alternative to daily insulin shots for the 8 million people in the United States with type 2 diabetes. Eli Lilly ... “This long-acting formulation could help address ...

Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly ... longer-acting insulins. Lilly's once-weekly ...